Effects of Tanshinone ⅡA Sodium Sulfonate Combined with Epalrestat on Renal Function and Hemodynamic Parameters in Patients with diabetes Nephropathy
Objective To investigate the effect of tanshinone Ⅱ A sulfonate sodium combined with epalrestat on renal function and hemodynamics in patients with diabetes nephropathy.Methods 88 patients with diabetes nephropathy admitted to our hospital from February 2020 to May 2022 were randomly divided into a control group and a test group,44 patients in each group.The patients in the control group were treated with epalrestat,and the patients in the test group were treated with sodium tanshinone Ⅱ A sulfonate combined with epalrestat.After 4 weeks of treatment,the renal function and hemodynamic indexes of the two groups were compared.Results Before treatment,there was no significant difference in renal function between the two groups(P＞0.05).After treatment,24h urine protein quantification of patients in the test group was(1.03±0.32)g,BUN was(7.62±0.57)mmol/L and Cre was(71.24±10.17)p Mol/L was higher than that in the control group(P＜0.05).Before treatment,there was no significant difference in hemodynamic indexes between the two groups(P＞0.05).After treatment,the whole blood reduced viscosity(10.25±1.57)mPa·s,blood viscosity(1.45±0.25)mPa·s and whole blood viscosity(4.83±0.95)mPa·s in the test group were lower than those in the control group(P＜0.05).The total effective rate of patients in the test group was 95.45％,which was significantly higher than 79.55％in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Tanshinone Ⅱ A sodium sulfonate combined with epalrestat can effectively improve the hemodynamics and enhance the renal function of patients with diabetes nephropathy,with significant clinical efficacy and high safety.
Diabetes nephropathyTanshinone Ⅱ A sodium sulfonateIparstaRenal functionHemodynamics
万方数据
维普
